Amylyx Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX), today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the SVB Securities Global Biopharma Conference. The conference is being conducted in a virtual format, and the fireside chat will take place on Tuesday, February 14, 2023, at 10:00am ET.

A live webcast of the presentation can be accessed under “Events” in the Investor section of the Company’s website, https://investors.amylyx.com/news-events/events, and will be available for replay for 90 days following the event.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. is committed to supporting and creating more moments for the neurodegenerative disease community through the discovery and development of innovative new treatments. Amylyx is headquartered in Cambridge, Massachusetts and has operations in Canada and EMEA. For more information, visit amylyx.com and follow us on LinkedIn and Twitter. For investors, please visit investors.amylyx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005048/en/

Media
Amylyx Media Team
+1 (857) 799-7274
[email protected]

Investors
Lindsey Allen
Amylyx Pharmaceuticals, Inc.
+1 (857) 320-6244
[email protected]

Source: Amylyx Pharmaceuticals, Inc.

You May Also Be Interested In

• Green Electricity Illuminates Indoor Ski Resort in Central China
• Best AI Meme Coin Presale 2026: MemeToro Combines AI Agents With BNB Chain Infrastructure
• Green Thumb Opens Its 24th Florida Location, RISE Dispensary Port St. Lucie, on August 22